Hemostemix is a clinical stage biotechnology company focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases. ACP , our lead clinical stage candidate, is an autologous cell therapy for the treatment critical limb ischemia. ACP is currently in a Phase clinical trail in Canada, South Africa and the United States.
Quote | Hemostemix Inc (OTCMKTS:HMTXF)
Last: | $0.0371 |
---|---|
Change Percent: | -0.27% |
Open: | $0.0372 |
Close: | $0.0372 |
High: | $0.0372 |
Low: | $0.0371 |
Volume: | 58,000 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
News | Hemostemix Inc (OTCMKTS:HMTXF)
Calgary, Alberta--(Newsfile Corp. - March 7, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the non-exclusive engagement of Oak Hill Asset Management Inc. ("OHAM"), an Exempt Market Dealer to provide capital markets advice rel...
Calgary, Alberta--(Newsfile Corp. - February 6, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the Journal of Biomedical Research and Environmental Sciences published the Company's Phase II randomized clinical trial results ...
Message Board Posts | Hemostemix Inc (OTCMKTS:HMTXF)
Subject | By | Source | When |
---|---|---|---|
The ongoing underperformance of $HMTXF's stock has raised red flags about its viability as a long-te | 10/31/2023 8:06:24 AM | ||
$HEM's stock price took a hit, falling by 15% to $0.085 in the previous trading session, translating | 10/30/2023 2:24:09 PM | ||
The persistent disappointment in $HEM's stock performance has cast doubt on its potential as a long- | 10/30/2023 9:55:13 AM | ||
lolapaluuza: Sounds very global. For a long time I couldn't solve the problem of tracking the workin | lolapaluuza | investorshangout | 05/05/2023 11:59:39 AM |
MatthewDavies: Hemostemix Inc. (TSXV: $HEM) (OTCQB: | MatthewDavies | investorshangout | 10/25/2022 5:29:19 PM |
News, Short Squeeze, Breakout and More Instantly...
Calgary, Alberta--(Newsfile Corp. - March 7, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the non-exclusive engagement of Oak Hill Asset Management Inc. ("OHAM"), an Exempt Market Dealer to provide capital markets advice rel...
Calgary, Alberta--(Newsfile Corp. - February 6, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the Journal of Biomedical Research and Environmental Sciences published the Company's Phase II randomized clinical trial results ...
Calgary, Alberta--(Newsfile Corp. - December 29, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to like to clarify its press release of October 3, 2023. It refered to the private placement of $320,125 . The Company closed the financing i...